Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04329923 · ClinicalTrials.gov registry record · Phase 2
The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine)
A Phase 2 study, sponsored by Ravi Amaravadi, MD.
- Terminated
- Registry status
- Phase 2
- Development phase
- 173
- Enrollment target
NCT04329923 is a Phase 2 study that was terminated before completion, run by Ravi Amaravadi, MD. The registered enrollment target is 173 participants.
The verdict
NCT04329923, a Phase 2 study, was terminated before completion, sponsored by Ravi Amaravadi, MD.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 173 participants
- Enrollment target
Study Summary
The PATCH trial (Prevention And Treatment of COVID-19 with Hydroxychloroquine) is funded investigator-initiated trial that includes 3 cohorts. Cohort 1: a double-blind placebo controlled trial of high dose HCQ as a treatment for home bound COVID-19 positive patients; Cohort 2: a randomized study testing different doses of HCQ in hospitalized patients; Cohort 3: a double blind placebo controlled trial of low dose HCQ as a preventative medicine in health care workers.
Interventions
- DRUG Placebo oral tablet
- DRUG Hydroxychloroquine Sulfate 400 mg twice a day
- DRUG Hydroxychloroquine Sulfate 600 mg twice a day
- DRUG Hydroxychloroquine Sulfate 600 mg once a day
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 173 participants |
| Start Date | 2020-04-09 |
| Est. Completion | 2020-11-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04329923
The ClinicalTrials.gov registry entry for NCT04329923 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 173 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ravi Amaravadi, MD, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo oral tablet is the first listed.
NCT04329923 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04329923 about?
NCT04329923 is a clinical study titled "The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine)". The PATCH trial (Prevention And Treatment of COVID-19 with Hydroxychloroquine) is funded investigator-initiated trial that includes 3 cohorts. Cohort 1: a double-blind placebo controlled trial of high dose HCQ as a treatment for home bound COVID-19 positive patients; Cohort 2: a randomized study tes...
What is the current status of trial NCT04329923?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 173 participants. The study started on 2020-04-09. Estimated completion is 2020-11-13.
What interventions are being tested in trial NCT04329923?
The interventions under investigation include: Placebo oral tablet (DRUG), Hydroxychloroquine Sulfate 400 mg twice a day (DRUG), Hydroxychloroquine Sulfate 600 mg twice a day (DRUG), Hydroxychloroquine Sulfate 600 mg once a day (DRUG).
Who is sponsoring clinical trial NCT04329923?
This trial is sponsored by Ravi Amaravadi, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.